SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is trending due to positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, which demonstrated significant efficacy and a favorable safety profile. The community is vigorously debating the stock's substantial surge, highlighting the drug's potential as a "best-in-class" oral therapy for a large market and speculating on future partnerships or a buyout. However, some investors express caution given the early-stage nature of the trial results and the historical tendency for Phase 1 catalysts to precede dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market activity following a favorable FDA meeting for its ANKTIVA + BCG bladder cancer application, which did not require new clinical trials, de-risking its path forward. The community is actively discussing a potential short squeeze, fueled by exceptionally high trading volume and strong conviction in the company's transformative cancer therapies. Investors are showing "diamond hands" as they anticipate further positive developments and a re-rating of the stock's value, pushing back against perceived short seller pressure.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending intensely ahead of its upcoming earnings, with community sentiment highly polarized on whether strong content performance and recent strategic maneuvers, like the revised all-cash bid for Warner Bros. Discovery assets, will drive a significant rebound. Investors are closely debating the potential impact of these developments on subscriber growth and profitability, while also considering how broader market pressures and recent bond purchases by President Trump might influence the stock's post-earnings trajectory.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid news of the U.S. government establishing a new digital asset reserve by holding seized Bitcoin, a shift from prior selling policies. This development comes as the community intensely debates BTC's price volatility, questioning its "safe haven" status against surging gold and silver amidst broader market uncertainty and geopolitical tensions. Despite these short-term pressures, discussions highlight ongoing significant institutional and large-scale investor acquisitions.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently trending due to market reports indicating potential acquisition talks with Zydus Lifesciences, sparking widespread community discussion about a possible bidding war and future valuation. This comes on the heels of robust preliminary financial updates, including accelerated revenue projections for IBSRELA, now expected to reach a billion by 2029, and a significant patent extension to 2041 for its key products. Investors widely regard this extended intellectual property protection as a pivotal development, potentially driving a substantial re-rating and further M&A interest in the biotech sector.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending amid discussions of its strengthened position in the AI data center sector, following its recent full ownership of a key Texas data center campus and a strategic co-development partnership. The community is actively debating a potential short squeeze and eagerly awaiting an anchor tenant announcement for its hyperscale project, underscoring its perceived resilience despite past challenges.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as new institutional developments, such as NYSE's tokenized securities platform, fuel optimism for its long-term utility, alongside record-high staking demand and near-zero unstaking queues. Despite this, community discussions are polarized, with debates centered on whether current market downturns and liquidations represent a prime buying opportunity or signal further weakness amidst broader crypto market volatility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is trending due to its persistent decline to multi-year lows, sharply contrasting with broader market gains. This downturn is fueling intense community frustration, with widespread calls for CEO Jeff Green's accountability amidst concerns over competitive pressures from "walled garden" platforms and anticipation building for upcoming earnings as a pivotal event.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid escalating geopolitical concerns related to potential US-EU trade tariffs and discussions around Greenland, which are generating broad market uncertainty. The community is actively debating the implications, with traders engaged in high-volume options activity as broader indexes experience a sell-off alongside global bond market movements.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant licensing agreement with Pfizer for its Matrix-M adjuvant, validating the platform's potential and sparking widespread community discussion. This news, coupled with growing interest from other pharmaceutical companies, has heightened speculation of a short squeeze while also increasing pressure on management to deliver further strategic partnerships.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Microcap Just Locked Up New IP in a Massive Pharma Market

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The ...

<ul class="summary-bullets"><li>Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases.</li><li>The new patent expands Can-Fite’s IP coverage in Brazil and opens up potential commercialization opportunities in the Latin American market.</li><li>On Tuesday, the company approved a 1-for-3,000 reverse split effective Jan. 5, 2026, on the Tel Aviv Stock Exchange, alongside an ADS ratio change on the NYSE at a 1-for-20 reverse split.</li></ul>NYSE-listed shares of Can-Fite BioPharma (CANF) surged 50% in premarket trading on Friday, after the company secured a Brazilian patent for its treatment of sexual dysfunction, opening the door to potential commercialization opportunities in Latin America.<a href="https://stocktwits.com/symbol/CANF">Can-Fite BioPharma</a> announced that Brazil’s Patent Office has granted a patent covering the use of its A3 adenosine receptor (A3AR) agonists for the treatment of sexual dysfunction. The new patent expands Can-Fite’s IP coverage in Brazil, a key Latin American pharmaceutical market with increasing demand for treatments targeting sexual health.<h2 class="st-heading-2">Can-Fite’s A3AR Agonist Platform</h2>Sexual dysfunction is linked to vascular, inflammatory, and metabolic pathways, and Can-Fite’s preclinical and clinical research suggests that A3AR activation may help regulate key signaling mechanisms involved in erectile and sexual function. Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases, while exploring additional non-oncologic applications.“The grant of this Brazilian patent further validates the therapeutic versatility of A3 adenosine receptor agonists and expands our intellectual-property footprint in a major pharmaceutical market. This patent complements our broader clinical and preclinical programs and may create future partnering or commercialization opportunities in Latin America,” said Pnina Fishman, Chairperson and Chief Scientific Officer at Can-Fite BioPharma.<h2 class="st-heading-2">Reverse Stock Spilt</h2>On Tuesday, Can-Fite BioPharma approved a 1-for-3,000 reverse split of its ordinary shares, which will&nbsp;be recorded on the Tel Aviv Stock Exchange on January 2, 2026, with trading in the newly consolidated shares set to begin on January 5, 2026.At the same time, Can-Fite will adjust the ratio of its American Depositary Shares (ADS) traded on the NYSE. The ADS ratio will change from one ADS representing 300 ordinary shares to one ADS representing two ordinary shares, an adjustment equivalent to a 1-for-20 ADS split.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user was speculating on the stock price post reverse split.<stembedurl>https://stocktwits.com/Dansaidso/message/640149218</stembedurl>Year-to-date, the stock has been under heavy selling pressure, losing more than 85%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/mag-7-2025-review-on-charts/cLeU7wOREwN">As 2025 Bids Adieu, A Look At How Mag 7 Stocks Are Positioned On Charts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stocks, shares background - stock photo (representative image courtesy of Sean Gladwell via Getty Images)

Can-Fite BioPharma Shares Surged 50% In Pre-Market On Brazilian Patent Win

The company said it was granted a patent covering the use of its A3 adenosine receptor agonists for the treatment of sexual dysfunction in Brazil.

Equity

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Current Price	$3.96
Prev Close	$4.00
Open	$4.10
Dividend Yield	0.00%
50-Day Moving Average	$5.83
Beta	0.61
Avg. Volume	483,414.36
PE Ratio	0.00

52-Week High	$46.60
52-Week Low	$3.36
Market Capitalization	$5.24M
EPS (Annual)	-$3,273.46
Price to Book	0.00
Revenue Per Employee	$135,439.80
Enterprise Value/EBITDA	N/A

CANF
Can-Fite BioPharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest CANF News

CANFCan-Fite BioPharma Ltd.